News

TAIPEI, Taiwan, March 24, 2022 – Formosa Pharmaceuticals, Inc. (6838.TWO) announce the approval of a resolution by the boards of directors of both Formosa Pharmaceuticals and EirGenix, Inc. (6589.TT) for the co-development of anticancer ADC, TSY-0110 (EG12043).  This agreement strengthens the existing relationship between both companies and fortifies TSY-0110’s clinical development pathway and subsequent licensing …

Formosa Pharmaceuticals and EirGenix establish a co-development alliance to develop TSY-0110 / EG12043 (ado-trastuzumab emtansine biosimilar) for HER2-positive breast cancer. Read More »

TAIPEI – October 5, 2021 – Formosa Pharmaceuticals (“Formosa”, stock code: 6838) announce its registration on the Emerging Stock Board of the Taipei Stock Exchange (TPEx) as of October 7.  The listing price is NT $32 per share (approx. USD $1.15). Formosa Pharmaceuticals (6838) was established in 2010 and has a paid-in capital of NT …

Formosa Pharmaceuticals announce registration on Emerging Stock Board of the Taipei Stock Exchange (TPEx) Read More »

(Corticosteroid for inflammation and pain after cataract surgery) TAIPEI – June 3, 2021 – Formosa Pharmaceuticals (“Formosa”, stock code:6838) and China Grand Pharma (“Grand”, HKG stock code:00512) announce that they have entered into an exclusive licensing agreement for the development and commercialization of Formosa’s APP13007 in the territory defined by Mainland China, Hong Kong, and …

Formosa Pharmaceuticals and China Grand Pharmaceutical and Healthcare Holdings Limited enter into licensing agreement for APP13007 Read More »

April 16, 2021 Formosa Pharmaceuticals (FP), a subsidiary of Formosa Laboratories (TWSE 4746), has successfully completed a Series C financing round, increasing its cash capital by NTD $600 million (approx. USD $21.1 million). In addition to the continuous support from major shareholder, Formosa Laboratories, numerous prominent venture capital firms participated in this round of capital …

Formosa Pharmaceuticals completes USD $21.1 million fundraising and increase in cash capital Read More »

Formosa Pharmaceuticals and AimMax Therapeutics report top-line results from a Phase 2 clinical trial of APP13007 for the treatment of inflammation and pain after cataract surgery. The End-of-Phase 2 meeting with the FDA is successful, setting the stage for pivotal Phase 3 trials to begin as early as 2020-Q4. APP13007 meets primary endpoints demonstrating rapid …

APP13007 completes Phase 2 clinical trial and EOP2 meeting. Read More »